Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy

Regulatory Peptides

Volumn 140, Issue 3, 2007, Pages 178-184

  Miettinen, Kati H ^a   Magga, Jarkko ^a   Vuolteenaho, Olli ^b   Vanninen, Esko J ^a   Punnonen, Kari R ^a   Ylitalo, Kari ^c   Tuomainen, Petri ^a   Peuhkurinen, Keijo J ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Exercise capacity; Heart failure; Regulatory peptides

Indexed keywords

ADRENALIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APELIN; BIOCHEMICAL MARKER; INTERLEUKIN 6; NORADRENALIN; PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADRENALIN BLOOD LEVEL; ADULT; AGED; ARTICLE; BLOOD LEVEL; CARDIOPULMONARY EXERCISE TEST; CLINICAL ASSESSMENT; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEART DISEASE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; NORADRENALIN BLOOD LEVEL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY;

ADULT; BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; CARRIER PROTEINS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-6; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NOREPINEPHRINE; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; RADIOIMMUNOASSAY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33947205566     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2006.12.004     Document Type: Article

References (49)

1. Tatemoto K., Hosoya M., Habata Y., Fujii R., Kakegawa T., Zou M.X., Kawamata Y., Fukusumi S., Hinuma S., Kitada C., Kurokawa T., Onda H., and Fujino M. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 251 (1998) 471-476
2. Habata Y., Fujii R., Hosoya M., Fukusumi S., Kawamata Y., Hinuma S., Kitada C., Nishizawa N., Murosaki S., Kurokawa T., Onda H., Tatemoto K., and Fujino M. Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim Biophys Acta 1452 (1999) 25-35
3. Reaux A., De Mota N., Skultetyova I., Lenkei Z., El Messari S., Gallatz K., Corvol P., Palkovits M., and Llorens-Cortes C. Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J Neurochem 77 (2001) 1085-1096
4. Taheri S., Murphy K., Cohen M., Sujkovic E., Kennedy A., Dhillo W., Dakin C., Sajedi A., Ghatei M., and Bloom S. The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats. Biochem Biophys Res Commun 291 (2002) 208-212
5. De Mota N., Reaux-Le Goazigo A., El Messari S., Chartrel N., Roesch D., Dujardin C., Kordon C., Vaudry H., Moos F., and Llorens-Cortes C. Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci U S A 101 (2004) 10464-10469
6. Goazigo A.R., Morinville A., Burlet A., Llorens-Cortes C., and Beaudet A. Dehydration-induced cross-regulation of apelin and vasopressin immunoreactivity levels in magnocellular hypothalamic neurons. Endocrinology 145 (2004) 4392-4400
7. Cayabyab M., Hinuma S., Farzan M., Choe H., Fukusumi S., Kitada C., Nishizawa N., Hosoya M., Nishimura O., Messele T., Pollakis G., Goudsmit J., Fujino M., and Sodroski J. Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. J Virol 74 (2000) 11972-11976
8. Zou M.X., Liu H.Y., Haraguchi Y., Soda Y., Tatemoto K., and Hoshino H. Apelin peptides block the entry of human immunodeficiency virus (HIV). FEBS Lett 473 (2000) 15-18
9. Lee D.K., Cheng R., Nguyen T., Fan T., Kariyawasam A.P., Liu Y., Osmond D.H., George S.R., and O'Dowd B.F. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 74 (2000) 34-41
10. Tatemoto K., Takayama K., Zou M.X., Kumaki I., Zhang W., Kumano K., and Fujimiya M. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 99 (2001) 87-92
11. 1)Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 132 (2001) 1255-1260
12. Kagiyama S., Fukuhara M., Matsumura K., Lin Y., Fujii K., and Iida M. Central and peripheral cardiovascular actions of apelin in conscious rats. Regul Pept 125 (2005) 55-59
13. Szokodi I., Tavi P., Földes G., Voutilainen-Myllylä S., Ilves M., Tokola H., Pikkarainen S., Piuhola J., Rysä J., Toth M., and Ruskoaho H. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 91 (2002) 434-440
14. Berry M.F., Pirolli T.J., Jayasankar V., Burdick J., Morine K.J., Gardner T.J., and Woo Y.J. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 110 Suppl 1 (2004) II187-II193
15. Ashley E.A., Powers J., Chen M., Kundu R., Finsterbach T., Caffarelli A., Deng A., Eichhorn J., Mahajan R., Agrawal R., Greve J., Robbins R., Pattersom A.J., Bernstein D., and Quertermous T. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 65 (2005) 73-82
16. Dai T., Ramirez-Correa G., and Gao W.D. Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol 553 (2006) 222-228
17. Jia Y.X., Pan C.S., Zhang J., Geng B., Zhao J., Gerns H., Yang J., Chang J.K., Tang C.S., and Qi Y.F. Apelin protects myocardial injury induced by isoproterenol in rats. Regul Pept 133 (2006) 147-154
18. Chen M.M., Ashley E.A., Deng D.X., Tsalenko A., Deng A., Tabibiazar R., Ben-Dor A., Fenster B., Yang E., King J.Y., Fowler M., Robbins R., Johnson F.L., Bruhn L., McDonagh T., Dargie H., Yakhini Z., Tsao P.S., and Quertermous T. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108 (2003) 1432-1439
19. Földes G., Horkay F., Szokodi I., Vuolteenaho O., Ilves M., Lindstedt K.A., Mäyränpää M., Sarman B., Seres L., Skoumal R., Lako-Futo Z., deChatel R., Ruskoaho H., and Toth M. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 308 (2003) 480-485
20. Goetze J.P., Rehfeld J.F., Carlsen J., Videbaek R., Andersen C.B., Boesgaard S., and Friis-Hansen L. Apelin: a new plasma marker of cardiopulmonary disease. Regul Pept 133 (2006) 134-138
21. Francia P, Salvati A, Balla C, De Paolis P, Pagannone E, Borro M, Gentile G, Simmaco M, De Biase L, Volpe M. Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin. Eur J Heart Fail in press.
22. Chong K.S., Gardner R.S., Morton J.J., Ashley E.A., and McDonagh T.A. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 8 (2006) 355-360
23. Iwanaga Y., Kihara Y., Takenaka H., and Kita T. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: possible role of angiotensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol 41 (2006) 798-806
24. van den Broek S.A., van Veldhuisen D.J., de Graeff P.A., Landsman M.L., Hillege H., and Lie K.I. Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 70 (1992) 359-363
25. Costanzo M.R., Augustine S., Bourge R., Bristow M., O'Connell J.B., Driscoll D., and Rose E. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 92 (1995) 3593-3612
26. Osada N., Chaitman B.R., Miller L.W., Yip D., Cishek M.B., Wolford T.L., and Donohue T.J. Cardiopulmonary exercise testing identifies low risk patients with heart failure and severely impaired exercise capacity considered for heart transplantation. J Am Coll Cardiol 31 (1998) 577-582
27. Mancini D.M., Eisen H., Kussmaul W., Mull R., Edmunds Jr. L.H., and Wilson J.R. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 83 (1991) 778-786
28. Levine B., Kalman J., Mayer L., Fillit H.M., and Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990) 236-241
29. Kaye D.M., Lambert G.W., Lefkovits J., Morris M., Jennings G., and Esler M.D. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 23 (1994) 570-578
30. Munger M.A., Johnson B., Amber I.J., Callahan K.S., and Gilbert E.M. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 77 (1996) 723-727
31. Cowie M.R., and Mendez G.F. BNP and congestive heart failure. Prog Cardiovasc Dis 44 (2002) 293-321
32. Ferrara R., Mastrorilli F., Pasanisi G., Censi S., D'Aiello N., Fucili A., Valgimigli M., and Ferrari R. Neurohormonal modulation in chronic heart failure. Eur Heart J 4 Suppl D (2002) D3-D11
33. Mann D.L. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol 65 (2003) 81-101
34. Manolio T.A., Baughman K.L., Rodeheffer R., Pearson T.A., Bristow J.D., Michels V.V., Abelmann W.H., and Harlan W.R. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute Workshop). Am J Cardiol 69 (1992) 1458-1466
35. Whipp B.J., Davis J.A., Torres F., and Wasserman K. A test to determine parameters of aerobic function during exercise. J Appl Physiol 50 (1981) 217-221
36. Ala-Kopsala M., Magga J., Peuhkurinen K., Leipälä J., Ruskoaho H., Leppäluoto J., and Vuolteenaho O. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem 50 (2004) 1576-1588
37. Benge W., Litchfield R.L., and Marcus M.L. Exercise capacity in patients with severe left ventricular dysfunction. Circulation 61 (1980) 955-959
38. Richardson P., McKenna W., Bristow M., Maisch B., Mautner B., O'Connell J., Olsen E., Thiene G., Goodwin J., Gyarfas I., Martin I., and Nordet P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 93 (1996) 841-842
39. Burkart F., and Kiowski W. Circulatory abnormalities and compensatory mechanisms in heart failure. Am J Med 90 (1991) 19S-22S
40. Williams S.G., Ng L.L., O'Brien R.J., Taylor S., Li Y.F., and Tan L.B. Comparison of plasma N-brain natriuretic peptide, peak oxygen consumption, and left ventricular ejection fraction for severity of chronic heart failure. Am J Cardiol 93 (2004) 1560-1561
41. van Kimmenade R.R., Januzzi Jr. J.L., Ellinor P.T., Sharma U.C., Bakker J.A., Low A.F., Martinez A., Crijns H.J., MacRae C.A., Menheere P.P., and Pinto Y.M. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 48 (2006) 1217-1224
42. Tsutamoto T., Wada A., Maeda K., Mabuchi N., Hayashi M., Tsutsui T., Ohnishi M., Sawaki M., Fujii M., Matsumoto T., Horie H., Sugimoto Y., and Kinoshita M. Transcardiac extraction of circulating endothelin-1 across the failing heart. Am J Cardiol 86 (2000) 524-528
43. Galindo-Fraga A., Arrieta O., Castillo-Martinez L., Narvaez R., Oseguera-Moguel J., and Orea-Tejeda A. Elevation of plasmatic endothelin in patients with heart failure. Arch Med Res 34 (2003) 367-372
44. Uusimaa P., Tokola H., Ylitalo A., Vuolteenaho O., Ruskoaho H., Risteli J., Linnaluoto M., and Peuhkurinen K. Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Plasma B-type natriuretic peptide reflects left ventricular hypertrophy and diastolic function in hypertension. Int J Cardiol 97 (2004) 251-256
45. van de Wal R.M., Plokker H.W., Lok D.J., Boomsma F., van der Horst F.A., van Veldhuisen D.J., van Gilst W.H., and Voors A.A. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 106 (2006) 367-372
46. Wasywich C.A., Webster M.W., Richards A.M., and Stewart R.A. Coronary sinus and ascending aortic levels of aldosterone, angiotensin II, and B-type natriuretic peptide in patients with aortic stenosis and in patients with coronary heart disease. Am J Cardiol 97 (2006) 1068-1072
47. Ruskoaho H. Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol Rev 44 (1992) 479-602
48. Kinnunen P., Vuolteenaho O., and Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 132 (1993) 1961-1970
49. Levin E.R., Gardner D.G., and Samson W.K. Natriuretic peptides. N Engl J Med 339 (1998) 321-328